MACO 355
Alternative Names: MACO-355Latest Information Update: 24 May 2024
At a glance
- Originator Macomics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Tumour associated macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Apr 2024 Preclinical trials in Cancer in United Kingdom (Parenteral)
- 12 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer released by Macomics
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical study in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)